Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Core Insights - Ernexa Therapeutics has appointed Dr. Ira S. Winer to its Scientific and Medical Advisory Board, enhancing its expertise in women's oncology and immunotherapy [1][2][3] Company Overview - Ernexa Therapeutics is focused on developing innovative cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create allogeneic induced mesenchymal stem cells (iMSCs) [7] - The company's lead product, ERNA-101, aims to activate the immune system to target cancer cells, with an initial focus on ovarian cancer [8] Leadership and Expertise - Dr. Winer is a recognized gynecologic oncologist and translational scientist, contributing significant clinical and research experience to Ernexa's mission [2][5] - His background includes a Ph.D. in cellular and molecular biology, emphasizing scientific innovation in gynecologic cancers [6] Strategic Goals - Ernexa aims to advance ERNA-101 through first-in-human trials and expand its pipeline into inflammatory and autoimmune indications, leveraging Dr. Winer's strategic guidance [3][4]